The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder

Current Opinion in Psychiatry

Volumn 24, Issue 4, 2011, Pages 286-290

  Hazell, Philip ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Hospital Rd   (Australia)

Author keywords

attention deficit disorder with hyperactivity; dextroamphetamine; longitudinal studies; methylphenidate

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; METHYLPHENIDATE; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ALTERNATIVE MEDICINE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; COMORBIDITY; ENVIRONMENTAL FACTOR; HUMAN; LONG TERM CARE; PATIENT COMPLIANCE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; HUMANS; METHYLPHENIDATE; TIME; TREATMENT OUTCOME;

EID: 79958715775     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32834742db     Document Type: Review

References (30)

1. Pliszka SR. The MTA at 8. J Am Acad Child Adolesc Psychiatry 2009; 48:1122.
2. Brownen J. Ritalin and other stimulant medications can do more harm than good in treatment of ADD/ADHD. www.buzzle.com/articles/ritalin- stimulantmedications- do-more-harm-than-good. html. [Accessed 18 January 2011]
3. The risks of ADHD amphetamines. speedupsitstill.com/the-risks-of- adhdamphetamines. [Accessed 19 January 2011]
4. Boseley S. Ritalin heart attacks warning urged after 51 deaths in US. Move to highlight risks of drug prescribed to hyperactive children. www. guardian.co.uk/society/2006/feb/11/health.medicineandhealth. [Accessed January 2011]
5. VAXA ATTEND Homeopathic Remedy newideas.net/adhd/attend. [Accessed January 2011]
6. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36:159-165. (Pubitemid 43126140)
7. Miller AR, Lalonde CE, McGrail KM. Childrens persistence with methylphenidate therapy: a population-based study. Can J Psychiatry 2004; 49:761-768. (Pubitemid 40094949)
8. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a populationbased study. J Dev Behav Pediatr 2006; 27:1-10. (Pubitemid 44315107)
9. Atzori P, Usala T, Carucci S, et al. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol 2009; 19:673-681.
10. Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48:484-500.
11. Pappadopulos E, Jensen PS, Chait AR, et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 2009; 48:501-510.
12. Hazell PL, McDowell MJ, Walton JM. Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of NSW. Med J Aust 1996; 165:477-480. (Pubitemid 26379024)
13. Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Services Res 2009; 9:95.
14. Sallee FR. The role of alpha2-adrenergic agonists in attention-deficit/ hyperactivity disorder. Postgrad Med 2010; 122:78-87.
15. Wilens TE, Hammerness P, Utzinger L, et al. An open study of adjunct OROSmethylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol 2009; 19:485-492.
16. Sawyer MG, Rey JM, Graetz BW, et al. Use of medication by young people with attention-deficit/hyperactivity disorder. Med J Aust 2002; 177:21-25. (Pubitemid 34763855)
17. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatmentresistant aggression in attention-deficit/hyperactivity disorder: a placebocontrolled pilot study. J Am Acad Child Adolesc Psychiatry 2007; 46: 558-565. (Pubitemid 46642572)
18. Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry 2009; 166:1392-1401.
19. Sinha D, Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J Paediatr Child Health 2005; 41:23-26. (Pubitemid 40223140)
20. Smith G, Jongeling B, Hartmann P, et al. Raine ADHD study: long-term outcomes associated with stimulant medication in the treatment of ADHD in children. Perth: Government of Western Australia Department of Health; 2010.
21. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007; 46:989-1002. (Pubitemid 47220683)
22. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005; 57:1215-1220. (Pubitemid 40798537)
23. Hazell P. Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 2007; 43:19-24. (Pubitemid 44973396)
24. Connor DF, Steeber J, McBurnett K. A review of attention-deficit/ hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder. J Dev Behav Pediatr 2010; 31:427-440.
25. The MTA Cooperative Group. Mediators and moderators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of Children With Attention Deficit Hyperactivity Disorder Study. Arch Gen Psychiatry 1999; 56:1088-1096.
26. Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 1996; 35:1460-1469. (Pubitemid 26360931)
27. Rieppi R, Greenhill LL, Ford RE, et al. Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry 2002; 41:269-277. (Pubitemid 38338148)
28. Hinshaw SP. Moderators and mediators of treatment outcome for youth with ADHD: understanding for whom and how interventions work. Ambul Pediatr 2007; 7 (1 Suppl):91-100. (Pubitemid 46140754)
29. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56:1073-1086.
30. Barbaresi WJ, Katusic SK, Colligan RC, et al. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr 2007; 28:274-287. (Pubitemid 47256030)